Condition: Avian Influenza A Virus · Sponsor: Butantan Institute
This study aims to demonstrate the safety and immunogenicity of two formulations of the monovalent influenza vaccine candidate A (H5N8) (inactivated, fragmented, and adjuvanted with IB160) from the Instituto Butantan in adults and older adults, to be developed for situations of pandemic, epidemic or outbreak of avian type A/H5 in humans, in the context of pandemic preparedness.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Centro de Terapias Avançadas E Inovadoras - Ct Terapias/Ufmg | Belo Horizonte, Minas Gerais, Brazil | Not Yet Recruiting |
| Plátano Centro de Pesquisa Clínica LTDA | Recife, Pernambuco, Brazil | Recruiting |
| Fundação Faculdade Regional de Medicina de São Jose do Rio Preto - (Centro integrado de Pesquisa CIP) | São José do Rio Preto, São Paulo, Brazil | Not Yet Recruiting |
| Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preta da Universidade de São Paulo - (Centro de Pesquisa Clínica - S) | Serrana, São Paulo, Brazil | Not Yet Recruiting |
| Centro de Pesquisas Clínicas do Hospital das Clínicas da FMUSP | São Paulo, Brazil | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06842173